Coldstream Capital Management Inc. Buys Shares of 4,174 Moderna, Inc. (NASDAQ:MRNA)

Posted by Defense World Staff on Mar 20th, 2023

Coldstream Capital Management Inc. purchased a new stake in Moderna, Inc. (NASDAQ:MRNA – Get Rating) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 4,174 shares of the company’s stock, valued at approximately $750,000.

Several other institutional investors and hedge funds have also modified their holdings of MRNA. Evoke Wealth LLC boosted its position in Moderna by 100.8% in the third quarter. Evoke Wealth LLC now owns 239 shares of the company’s stock valued at $28,000 after buying an additional 120 shares in the last quarter. Guardian Wealth Advisors LLC acquired a new stake in shares of Moderna during the 3rd quarter valued at $28,000. Castleview Partners LLC grew its position in Moderna by 14,182.9% during the 2nd quarter. Castleview Partners LLC now owns 4,999 shares of the company’s stock worth $35,000 after acquiring an additional 4,964 shares during the last quarter. Equitec Proprietary Markets LLC acquired a new position in Moderna in the 3rd quarter worth about $35,000. Finally, Hexagon Capital Partners LLC raised its position in Moderna by 31.8% in the third quarter. Hexagon Capital Partners LLC now owns 323 shares of the company’s stock valued at $38,000 after purchasing an additional 78 shares during the last quarter. 63.11% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. upped their price objective on Moderna from $132.00 to $138.00 and gave the company a “neutral” rating in a research note on Wednesday, February 8th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Moderna from $225.00 to $200.00 and set a “buy” rating for the company in a research report on Tuesday, February 28th. SVB Securities lowered shares of Moderna from a “market perform” rating to an “underperform” rating and cut their price target for the stock from $111.00 to $93.00 in a report on Friday, February 24th. Piper Sandler increased their price objective on Moderna from $214.00 to $217.00 and gave the company an “overweight” rating in a report on Tuesday, December 20th. Finally, SVB Leerink downgraded Moderna from a “market perform” rating to an “underperform” rating and cut their target price for the stock from $111.00 to $93.00 in a report on Friday, February 24th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $180.80.

Moderna Stock Down 1.2 %

Shares of NASDAQ MRNA opened at $150.02 on Monday. The business’s fifty day moving average price is $167.52 and its 200-day moving average price is $160.73. Moderna, Inc. has a one year low of $115.03 and a one year high of $217.25. The stock has a market capitalization of $57.86 billion, a PE ratio of 7.52 and a beta of 1.70. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.73 and a quick ratio of 2.54.

Moderna (NASDAQ:MRNA – Get Rating) last released its quarterly earnings data on Thursday, February 23rd. The company reported $3.61 earnings per share for the quarter, missing analysts’ consensus estimates of $4.66 by ($1.05). The business had revenue of $5.08 billion during the quarter, compared to analysts’ expectations of $5.02 billion. Moderna had a net margin of 43.41% and a return on equity of 46.34%. The firm’s quarterly revenue was down 29.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $11.29 earnings per share. On average, equities research analysts anticipate that Moderna, Inc. will post -2.43 EPS for the current year.

Insider Buying and Selling at Moderna

In other news, CEO Stephane Bancel sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 22nd. The shares were sold at an average price of $205.31, for a total value of $8,212,400.00. Following the completion of the transaction, the chief executive officer now directly owns 5,411,946 shares in the company, valued at $1,111,126,633.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Moderna news, President Stephen Hoge sold 245 shares of the company’s stock in a transaction dated Friday, February 10th. The stock was sold at an average price of $163.90, for a total value of $40,155.50. Following the transaction, the president now directly owns 1,627,693 shares in the company, valued at approximately $266,778,882.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Stephane Bancel sold 40,000 shares of the firm’s stock in a transaction dated Thursday, December 22nd. The shares were sold at an average price of $205.31, for a total value of $8,212,400.00. Following the completion of the sale, the chief executive officer now directly owns 5,411,946 shares in the company, valued at approximately $1,111,126,633.26. The disclosure for this sale can be found here. Insiders sold 546,337 shares of company stock valued at $94,751,432 in the last quarter. 17.30% of the stock is currently owned by corporate insiders.

About Moderna

(Get Rating)

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.